Skip to content
Keeping Current cover art

All Episodes

Keeping Current — 630 episodes · page 3 of 7

#
Title
201

Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Multidisciplinary Perspectives on Managing and Maximizing Care

202

Diabetes Dialogue: Can We Reduce the Disease Burden with Weekly Basal Insulin?

203

Understanding the Role of Biologics in Hidradenitis Suppurativa: A Journal Club Review of Recent Data and Clinical Impacts

204

The Evolving Treatment Landscape for Patients With Psoriatic Disease

205

Value of Influenza Vaccination in Children: Impact on Transmission and Burden in the Whole Population

206

Neurocognitive Disorders in People Living With HIV: Cause and Consequence

207

New Therapies for Neovascular AMD and DME: What Have We Learned?

208

Identifying Progressive Pulmonary Fibrosis on Imaging and Collaborating With the Multidisciplinary Team

209

Demystifying Drug-Drug Interactions for COVID-19 Antivirals

210

CD19-Targeting in Relapsed/Refractory DLBCL: Optimizing the Use of Noncellular Therapies

211

Clinical Context of the Consensus: A Review of the Latest Recommendations for Waldenström Macroglobulinemia

212

Dengue Vaccination in Endemic Populations: Implementation Strategies in Diverse Settings

213

When Hyperkalemia Impairs Optimal Treatment of HF and CKD: What New Guidelines Recommend

214

Epilepsy and Depression: Managing Common Situations

215

Neprilysin Inhibition: In Heart Failure and Beyond

216

What Are the Patients' Unmet Needs in C3 Glomerulopathy? Clinical Pearls on Current Management and Future Perspectives

217

Hot Topics in Breast Cancer Clinical Research: Challenges, Opportunities, and Implications for Practice

218

Optimizing Immunotherapy Combination Strategies for Metastatic NSCLC: From Evidence to Practice

219

Biosimilars 101: From Neurologists, for Neurologists

220

Diabetes Dialogue: Breaking Down Barriers to the Early Use of GLP-1 RAs in Primary Care

221

COVID-19 and Antivirals: Expert Evaluation of Data in High-Risk Patient Populations

222

New Lipid-Lowering Therapies in Atherosclerotic Cardiovascular Disease: Who, How, When, and for How Long?

223

Early-Onset Schizophrenia: Integrated Service Provision and Optimizing Care

224

Retinal Disease: An Update on Emerging Technologies

225

Generalized Pustular Psoriasis: What Do You Know About the Unmet Needs for Patients?

226

COVID-19 in the Current Era: Expert Insights on Oral Antivirals for Nonhospitalized Patients

227

The Simple Mathematics of Lipid-Lowering Therapies and Targets in ASCVD: What Every Healthcare Professional Needs to Know

228

Advances in the Management of Immunoglobulin G-Mediated Autoimmune Diseases

229

BTK Inhibitors for Chronic Lymphocytic Leukemia: Rapid-Fire Highlights From the Past Year

230

Managing Generalized Pustular Psoriasis: A Micro Learning Series

231

Sudden Unexpected Death in Epilepsy (SUDEP): The Essentials for Sensitive and Informed Conversations

232

Navigating the Changing Landscape in Myasthenia Gravis: An Expert Case-Based Discussion

233

Finding the Needle in the Haystack: Following the Journey of a Patient With C3G

234

Managing Early-Stage Resectable Non-Small Cell Lung Cancer: Through the Eyes of the Patient and the Care Team

235

Neonatal Fc Receptor in IgG-Mediated Autoimmune Disorders: Looking at a Common Denominator

236

Nutrients and Infant Neurodevelopment: Comparative Assessment on Impact of Individual Nutrients Over the Long Term

237

Latest Advances in Systemic Treatment for Breast Cancer: Evidence and Implications

238

Clinical Pearls: Getting Low-Density Lipoprotein-Cholesterol Levels to Target and Keeping Them There

239

Managing Adverse Events of Novel Antibody-Drug Conjugates in Breast Cancer

240

Optimizing Treatment Selection in Immune Thrombocytopenia: A Patient Case Discussion

241

Epilepsy and Its Burden: The Voice of the Caregiver

242

Development of Heart Failure Following Myocardial Infarction: What Is the Unmet Need?

243

Impact of Nutritional Management for Cow's Milk Allergy: Can It Interrupt the Allergic March?

244

Long-Term Management of Reflux and Deprescribing PPI Therapy: Expert Perspectives

245

Dengue: Vaccinating Travelers to Endemic Regions

246

A Patient With Type 2 Diabetes and Chronic Kidney Disease in Clinical Practice

247

Demystifying the Science of New Anti-Seizure Medications and Application to Clinical Practice

248

Development of Heart Failure Following Myocardial Infarction: Why Risks Still Remain High

249

Expert Exchange: Clinical Implications of the Latest Advances in Metastatic Breast Cancer

250

Meeting the Experts and Taking Action in Heart Failure

251

Classification and Nomenclature of IC-MPGN and C3G: A Spectrum of Diseases or Distinct Entities?

252

Adherence to Lipid-Lowering Therapies: How Can We Tackle This Barrier Better?

253

Adherence to Lipid-Lowering Therapies: How Can We Tackle This Barrier Better?

254

A Patient Is Waiting for a Liver Transplant: What Can We Do Now and What Could We Have Done Better?

255

Reducing the Risks of Hyperkalemia in the Treatment of Heart Failure and Chronic Kidney Disease: What It Means for Management Teams

256

Dengue Prevention: Integrating Vaccination Into Comprehensive Control Strategies Across Populations

257

Early-Stage Resectable Non-Small Cell Lung Cancer: Sharing Patient Perspectives

258

Gaining Control With Early Combination Lipid-Lowering Therapy: Applying Learnings From the Queen's Gambit

259

Looking Forward to Thriving With HIV: Interventions to Improve and Maintain Health in People With HIV

260

Three Cardiovascular Risk Cases: Why and Who Should We Be Testing for Lp(a)

261

Well Begun Is Half Done: Why and How Do We Assess Activity of the Complement Pathway in the Clinic?

262

What's New in Diabetic Eye Disease Technologies

263

Biosimilars in Multiple Sclerosis: Entering a New Era of Biologic Therapy

264

Are We Ready for Biosimilars in Multiple Sclerosis? Experts Discuss Lessons From Other Immune-Mediated Diseases

265

Global Perspectives on Anti-Vascular Endothelial Growth Factor: If, When, and How to Switch

266

Clinical Trials in Focus: Durability of Intravitreal Anti-Vascular Endothelial Growth Factor Therapies

267

Safeguarding the CKD Patient With or Without Diabetes in Primary Care: Quick Questions, Rapid Replies

268

Optimizing Treatments in Advanced Systemic Mastocytosis With Associated Hematological Neoplasm

269

Diabetes Dialogue Part 2: Who Are Candidates for GLP-1 Receptor Agonist Therapy in Primary Care?

270

Challenging the Harmful Myths About ASCVD Management: The Experts Set the Record Straight

271

What Is the Expert Accord on Identifying and Protecting the Patient at Early Stage of CKD?

272

Optimizing Adjuvant Treatment of Early Breast Cancer: Where Are We Today?

273

Pros and Cons of COVID-19 Vaccination in Children: Weighing the Evidence

274

The Road to Safety: Understanding the Common and Less Common Side Effects of COVID-19 and Other Vaccines

275

Recovering Immune Responses in Heavily Treatment-Experienced HIV-Positive Individuals

276

COVID-19 Immunization in Oncology and Stem Cell Transplant Settings: Experts Provide Practical Guidance

277

Chronic Kidney Disease – Looking Beyond Diabetes: Expert Interpretation of Latest Evidence From Kidney Outcome Trials

278

Dengue Immunization: Special Populations

279

Evolving Hesitancies and Objections to COVID-19 Booster Shots: Separating Facts From Fiction

280

Recent Updates in HR-Positive/HER2-Negative Early Breast Cancer: A Deep Dive Into Understanding the Data and Their Implications

281

Early-Stage Resectable Non-Small Cell Lung Cancer: Navigating a Changing Treatment Landscape

282

Advanced Age-Related Macular Degeneration: How to Use Imaging to Screen and Monitor Patients

283

Insights and Understanding of the Impact of Inflammation in HIV-Positive Individuals

284

Ideal Dengue Vaccine Characteristics

285

Spotlight on Chronic Lymphocytic Leukemia: Exploring the Continued Evolution of Bruton Tyrosine Kinase Inhibitors for Our Patients

286

Where Are We Now in the Use of Interleukin-17 Inhibitors for Psoriatic Disease?

287

Improving the Diagnosis and Management of Cow's Milk Allergy

288

The Evolving Role of Digital Health Solutions for Patients With Diabetes on Insulin

289

EMPA-Kidney in Context: Expanding Our Understanding of Sodium-Glucose Cotransporter 2 Inhibition in Chronic Kidney Disease Management

290

What COVID-19 Vaccines Can and Cannot Do: Setting Realistic Goals in the Current Pandemic

291

The Latest Data on Lipid-Lowering Therapies for ASCVD and What it Means for Practicing Clinicians

292

COVID-19 Vaccine Clinical Compendium: Comparing Vaccines, Safety Status, and Future Perspectives

293

To Boost or Not to Boost: The Debate Continues

294

Advances in the Management of Complement-Mediated Kidney Diseases: A Year in Review

295

Geographic Atrophy: Expert Perspectives and Latest Data

296

Complex Clinical Cases for Specialists: Getting Patients to Target LDL-C Despite Barriers

297

Axial Spondyloarthritis: What Do You Know?

298

Raising the Bar: Implementing Treatment Goals in Clinical Practice for Spondyloarthritis

299

COVID-19 Boosters: Why Do We Need Them?

300

Why Lipoprotein (a) Matters Regarding Cardiovascular Risk, and What's New?